Experts in TLR Biology

We are developing immunotherapies based on cutting-edge Toll-like receptor (TLR) biology and its ability to modulate the immune system. Learn More >

Cancer Immunotherapy

Through our expertise in TLR biology we are developing compounds designed to stimulate multiple innate mechanisms of tumor killing and development of immune memory associated with tumor-specific antigens. Learn More >

‹ ›

Hepatitis B Vaccine

HBsAg-1018 is an investigational adult hepatitis B vaccine that combines hepatitis B surface antigen with 1018, our proprietary TLR9 agonist.

Learn More ›

Toll-like Receptor (TLR) Platform

Our TLR platform is broadly applicable across multiple diseases including infectious diseases, cancer and asthma.

Learn More ›

News

Sep04

Dynavax Provides Regulatory Update on HEPLISAV-B

Aug05

Dynavax Reports Second Quarter 2016 Financial Results

Aug05

Dynavax Announces FDA Advisory Committee Meeting to Review HEPLISAV-B

View All News

Our values

At Dynavax we are proud of the work we do. Our corporate values provide the foundation of our culture and how we operate as a company.

Learn More ›